Biopharma News

Dec 30, 2014
BioPharm International
Although competing therapies will continue to be released in the immuno-oncology space, efficacy profiles, combination regimens, and administration setting may influence a drug’s preferred status more than price.
Dec 23, 2014
BioPharm International
The partnership will focus on the discovery of antibodies against proteins that are not easily purified in functional form.
Dec 23, 2014
By BioPharm International Editors
Protein Sciences will evaluate sourcing Flublok from its Japanese licensee, UMN Pharma, which already runs a large-scale facility for the vaccine.
Dec 19, 2014
BioPharm International
Roche will use Dutalys’ DutaMab technology for the engineering of bispecific therapeutic antibodies.Roche Acquires Bispecific Antibody Developer Dutalys
Dec 19, 2014
BioPharm International
Roche will use Dutalys’ DutaMab technology for the engineering of bispecific therapeutic antibodies.
Dec 19, 2014
BioPharm International
The first stem-cell medication approved in the EU promotes regeneration and healing to the outer layer of the cornea.
Dec 19, 2014
BioPharm International
By BioPharm International Editors
Merck announced that it acquired OncoEthix, a biotechnology company specializing in oncology drug development, for up to $375 million.
Dec 19, 2014
By BioPharm International Editors
The Cell Therapy Catapult, a UK non-profit center for advancing cell and gene therapies, will manage the manufacturing center, which will be used for late-phase clinical trials and commercial supply.
Dec 17, 2014
By BioPharm International Editors
The multi-product biopharmaceutical manufacturing facility is scheduled to start up in 2017.
Dec 17, 2014
BioPharm International
Halozyme will receive an initial payment of $15 million for Enhanze, its technology that enables biologics to be delivered as a simple subcutaneous injection.
native1_300x100
lorem ipsum